for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alkermes Plc

ALKS.OQ

Latest Trade

20.16USD

Change

-0.84(-4.00%)

Volume

814,951

Today's Range

19.79

 - 

20.95

52 Week Range

17.11

 - 

37.63

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Alkermes: Receipt Of $150 Mln Milestone Payment From Biogen Related To FDA Approval Of Vumerity

Nov 12 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES ANNOUNCES RECEIPT OF $150 MILLION MILESTONE PAYMENT FROM BIOGEN RELATED TO FDA APPROVAL OF VUMERITY.ALKERMES PLC - FINANCIAL EXPECTATIONS FOR 2019, PROVIDED ON OCT. 23 REFLECT MILESTONE PAYMENT.

Biogen And Alkermes Announce FDA Approval Of Vumerity For Multiple Sclerosis

Oct 30 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN AND ALKERMES ANNOUNCE FDA APPROVAL OF VUMERITY™ (DIROXIMEL FUMARATE) FOR MULTIPLE SCLEROSIS.BIOGEN INC - BIOGEN WILL PAY ALKERMES $150 MILLION IN CONNECTION WITH FDA'S APPROVAL OF VUMERITY.

Biogen And Alkermes Announce FDA Approval Of Vumerity For Multiple Sclerosis

Oct 30 (Reuters) - Alkermes Plc <ALKS.O>::BIOGEN AND ALKERMES ANNOUNCE FDA APPROVAL OF VUMERITY™ (DIROXIMEL FUMARATE) FOR MULTIPLE SCLEROSIS.ALKERMES PLC - VUMERITY OFFERS A COMBINATION OF WELL-CHARACTERIZED EFFICACY, SAFETY AND TOLERABILITY.ALKERMES PLC - BIOGEN INTENDS TO MAKE VUMERITY AVAILABLE IN UNITED STATES IN NEAR FUTURE.

Alkermes Reports Q3 Loss Per Share $0.34

Oct 23 (Reuters) - Alkermes Plc <ALKS.O>::REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND IMPLEMENTATION OF RESTRUCTURING.Q3 NON-GAAP LOSS PER SHARE $0.04.Q3 GAAP LOSS PER SHARE $0.34.Q3 REVENUE $255.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $252.7 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.21 -- REFINITIV IBES DATA.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $0.44 TO $0.57.SEES FY 2019 LOSS PER SHARE $0.86 TO $1.05.COMPANY UPDATES FINANCIAL EXPECTATIONS FOR 2019.ALKERMES - IN OCT. 2019, CO COMPLETED A REVIEW OF COMPANY'S OPERATIONS, COST STRUCTURE AND GROWTH OPPORTUNITIES AND IMPLEMENTED A RESTRUCTURING PLAN.OCT. 2019 RESTRUCTURING INCLUDED ELIMINATION OF APPROXIMATELY 160 CURRENT POSITIONS ACROSS ORGANIZATION.COMPANY EXPECTS TO RECORD A CHARGE OF APPROXIMATELY $15 MILLION IN Q4 OF 2019 AS A RESULT OF RESTRUCTURING.COMPANY CONTINUES TO EXPECT TOTAL REVENUES TO RANGE FROM $1.14 BILLION TO $1.19 BILLION IN 2019.COMPANY NOW EXPECTS 2019 CAPITAL EXPENDITURES TO RANGE FROM $80 MILLION TO $90 MILLION, REVISED FROM PRIOR EXPECTATION OF $90 MILLION TO $100 MILLION.FY2019 EARNINGS PER SHARE VIEW $0.34, REVENUE VIEW $1.18 BILLION -- REFINITIV IBES DATA.

Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center

Oct 21 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES ANNOUNCES CLINICAL COLLABORATION WITH FRED HUTCHINSON CANCER RESEARCH CENTER FOR NOVEL IMMUNO-ONCOLOGY DRUG CANDIDATE ALKS 4230.

Alkermes PLC Says Received Notice From FDA Of Tentative Approval Of Vumerity

Oct 17 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES PLC - RECEIVED NOTICE FROM FDA OF ITS TENTATIVE APPROVAL OF VUMERITY FOR TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS..ALKERMES - TENTATIVE APPROVAL LETTER STATED THAT FINAL APPROVAL OF VUMERITY IS SUBJECT TO EXPIRATION OF PERIOD OF PATENT PROTECTION AND/OR EXCLUSIVITY.

Alkermes Announces Settlement With Amneal Over Vivitrol Patent Dispute

July 29 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES ANNOUNCES SETTLEMENT WITH AMNEAL OVER VIVITROL® PATENT DISPUTE.ALKERMES PLC - PATENT TRIAL AND APPEAL BOARD ORAL HEARING CANCELLED.ALKERMES PLC - ADDITIONAL TERMS OF AGREEMENT ARE CONFIDENTIAL.ALKERMES - ENTERED INTO SETTLEMENT WITH AMNEAL PHARMA TO RESOLVE AMNEAL'S INTER PARTES REVIEW PETITION CHALLENGING U.S. PATENT NUMBER 7,919,499.

Alkermes Q2 Non-GAAP Earnings Per Share $0.09

July 25 (Reuters) - Alkermes Plc <ALKS.O>::REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $0.09.Q2 GAAP LOSS PER SHARE $0.27.Q2 REVENUE $279.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $251.4 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.

Alkermes Expands Planned New Drug Application For ALKS 3831 To Include Treatment Of Bipolar I Disorder

July 15 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES EXPANDS PLANNED NEW DRUG APPLICATION FOR ALKS 3831 TO INCLUDE TREATMENT OF BIPOLAR I DISORDER.ALKERMES PLC - PLANS TO SUBMIT NEW DRUG APPLICATION FOR SCHIZOPHRENIA AND BIPOLAR I DISORDER INDICATIONS IN Q4 OF 2019.ALKERMES PLC - ALKS 3831 NDA WILL INCLUDE DATA FROM COMPLETED ALKS 3831 ENLIGHTEN CLINICAL DEVELOPMENT PROGRAM.

Alkermes Advances ALKS 4230 Into Monotherapy Expansion Phase Of Study In Patients With Renal Cell Carcinoma Or Melanoma

June 12 (Reuters) - Alkermes Plc <ALKS.O>::ALKERMES ADVANCES ALKS 4230 INTO MONOTHERAPY EXPANSION PHASE OF ARTISTRY-1 IN PATIENTS WITH RENAL CELL CARCINOMA OR MELANOMA.ALKERMES - INITIATION OF ONGOING STUDY FOLLOWS IDENTIFICATION OF 6 ΜG/KG/DAY ADMINISTERED INTRAVENOUSLY AS RECOMMENDED MONOTHERAPY DOSE OF ALKS 4230.ALKERMES PLC - MAXIMUM TOLERATED DOSE OF ALKS 4230 HAS NOT YET BEEN REACHED.ALKERMES PLC - DOSE-ESCALATION STAGE OF ARTISTRY-1 STUDY IS CONTINUING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up